Ustekinumab – a new biological therapy of ulcerative colitis

Česká verze

Authors: Lukáš M.
Authors place of work: Klinické a výzkumné centrum pro idiopatické střevní záněty ISCARE a. s. a 1. LF UK, Praha
Published in the journal: Gastroent Hepatol 2020; 74(1): 39-43
Category: IBD: původní práce
doi: https://doi.org/10.14735/amgh202039

Summary

Based on the results of the UNIFI study, ustekinumab (UST) has been accepted into clinical practice for the therapy of moderate to severe ulcerative colitis in the Czech Republic since autumn 2019. This report describes the first anti-interleukine therapy in UC patients. In the UNIFI study, UST was shown to be a highly effective and safe therapy during the inductive and maintenance phases with side effects not different from those of the placebo. Previous failure of biologic therapy in a patient is a negative predictor of UST effectiveness, as observed with other monoclonal antibodies. UST therapy was associated with a prompt clinical response within the 2^nd week of therapy and with a concomitant reduction in the levels of inflammatory surrogate markers. UST was also highly effective for endoscopic and histologic remission. The UNIFI study is the first randomized controlled trial of UST, which demonstrated its effectiveness as a biologic therapy in patients who had been previously exposed to vedolizumab therapy.

Conflict of Interest: The author declares that the article/ manuscript complies with ethical standards, patient anonymity has been respected, and he states that he has no financial, advisory or other com mercial interests in relation to the subject matter.

Publication Ethics: This article/manuscript has not been published or is currently be ing submitted for another review.

The author agrees to publish his name and e-mail in the published article/manuscript.

Dedication: The article/manuscript was created with the supported of Jans sen-Cilag s.r.o. company.

The Editorial Board declares that the manuscript met the ICMJE „uniform requirements“ for biomedical papers.

Keywords:

Ulcerative colitis – ustekinumab – biologic therapy – antiinterleukine therapy

Zdroje

1. Singh S, Allegretti JR, Siddique SM et al. AGA technical review on the management of moderate to severe ulcerative colitis. Gastroenterology 2020. In press. doi: 10.1053/j.gastro.2020.01. 007.

2. Lukáš M. Druhá generace biologické léčby: anti-inregriny a anti-integriny. In: Lukáš M (ed). Pokroky v diagnostice a léčbě idiopatických střevních zánětů. Praha: Galén 2019: 290.

3. Sands SE, Sandborn WJ, Panaccione R et al. Ustekinumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2019; 381 (13): 1201–1214. doi: 10.1056/NEJMoa 1900750.

4. Sandborn WJ, Sands BE, Panaccione R et al. Efficacy and safety of ustekinumab as maintenance therapy in ulcerative colitis: week 44 results from UNIFI. J Crohn’s Colitis 2019; 13 (Suppl 1): S25–S26. doi: 10.1093/ecco-jcc/jjy222. 034.

5. Li K, Friedman JR, Marano C et al. Effects of ustekinumab induction therapy on endoscopic and histological healing in the UNIFI Phase 3 study in ulcerative colitis. J Crohn’s Colitis 2019; 13 (Suppl 1): S73. doi: 10.1093/ ecco-jcc/jjy222.105.

6. Sands BE, Sandborn WJ, Panaccione R et al. Efficacy and safety of ustekinumab for ulcerative colitis through 2 years: UNIFI long-term extension. Presented at: UEGW, October 19^th–23^rd 2019, Barcelona.

7. Adedokun OJ, Xu Z, Marano C et al. Pharmacokinetics and exposure-response relationships of intravenously administered ustekinumab during induction treatment in patients with ulcerative colitis: results from the UNIFI induction study. J Crohn’s Colitis 2019; 13 (Suppl 1): S255–S256. doi: 10.1093/ecco-jcc/ jjy222.435.